Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, Yoshiike F, Hama M, Nishie K, Kondo D, Agatsuma T, Kato A, Takata M, Kanda S, Hanaoka M, Koizumi T. Araki T, et al. Among authors: wasamoto s. Thorac Cancer. 2022 Jul;13(14):2031-2040. doi: 10.1111/1759-7714.14484. Epub 2022 May 26. Thorac Cancer. 2022. PMID: 35616056 Free PMC article.
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: wasamoto s. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Imai H, Minemura H, Kishikawa T, Yamada Y, Suzuki K, Umeda Y, Wasamoto S, Kasahara N, Ishihara S, Yamaguchi O, Naruse I, Uchino J, Mori K, Kanazawa K, Shibata Y, Kasai T, Kaburagi T, Kaira K, Minato K. Imai H, et al. Among authors: wasamoto s. Thorac Cancer. 2020 Oct;11(10):2867-2876. doi: 10.1111/1759-7714.13622. Epub 2020 Aug 26. Thorac Cancer. 2020. PMID: 32844570 Free PMC article.
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: wasamoto s. Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19. Cancer Chemother Pharmacol. 2020. PMID: 32193618
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K. Imai H, et al. Among authors: wasamoto s. J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18. J Cancer Res Clin Oncol. 2020. PMID: 31853661
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S, Kishikawa T, Shiono A, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Minato K, Kagamu H. Imai H, et al. Among authors: wasamoto s. Invest New Drugs. 2022 Oct;40(5):1066-1079. doi: 10.1007/s10637-022-01269-9. Epub 2022 Jun 24. Invest New Drugs. 2022. PMID: 35749041 Free PMC article.
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H, Yamada Y, Kishikawa T, Umeda Y, Takechi H, Yamaguchi O, Mouri A, Kaira K, Taniguchi H, Minato K, Kagamu H. Shiono A, et al. Among authors: wasamoto s. Cancer Med. 2023 Jan;12(1):73-83. doi: 10.1002/cam4.4938. Epub 2022 Jun 14. Cancer Med. 2023. PMID: 35699088 Free PMC article.
Luminal Findings of a Bronchogenic Cyst.
Yanagisawa S, Wasamoto S. Yanagisawa S, et al. Among authors: wasamoto s. Am J Respir Crit Care Med. 2021 Sep 15;204(6):e59-e60. doi: 10.1164/rccm.202101-0127IM. Am J Respir Crit Care Med. 2021. PMID: 33882265 No abstract available.
Osimertinib-induced lymphocytopenia and pneumocystis jirovecii pneumonia.
Takechi H, Endoh H, Hata Y, Wasamoto S, Yanagisawa S. Takechi H, et al. Among authors: wasamoto s. Pulmonology. 2022 Sep-Oct;28(5):403-405. doi: 10.1016/j.pulmoe.2022.04.005. Epub 2022 Jun 11. Pulmonology. 2022. PMID: 35701337 Free article. No abstract available.
Wheezing and Weightlifting.
Yanagisawa S, Wasamoto S, Takechi H, Hata Y. Yanagisawa S, et al. Among authors: wasamoto s. Intern Med. 2022 Mar 15;61(6):931-932. doi: 10.2169/internalmedicine.8179-21. Epub 2021 Sep 4. Intern Med. 2022. PMID: 34483215 Free PMC article. No abstract available.
16 results